Analysts’ Weekly Ratings Changes for Denali Therapeutics (DNLI)

Several analysts have recently updated their ratings and price targets for Denali Therapeutics (NASDAQ: DNLI):

• 7/23/2026 – Denali Therapeutics had its price target raised by Morgan Stanley from $35.00 to $36.00. They now have an “overweight” rating on the stock.
• 7/17/2026 – Denali Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/16/2026 – Denali Therapeutics had its price target raised by Deutsche Bank Aktiengesellschaft from $31.00 to $35.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Denali Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $26.00 price target on the stock.
• 7/13/2026 – Denali Therapeutics is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $29.00 price target on the stock.
• 6/22/2026 – Denali Therapeutics was given a new $41.00 price target by Stifel Nicolaus.
• 6/22/2026 – Denali Therapeutics had its “hold” rating reaffirmed by Sanford C. Bernstein.
• 6/16/2026 – Denali Therapeutics had its “buy” rating reaffirmed by UBS Group AG.

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.